ClinicalTrials.gg
CompletedNCT05661344Updated Nov 28, 2025Results posted

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

A Phase 1 interventional study of BI 1015550 in Hepatic Insufficiency, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatic Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Boehringer Ingelheim.

Enrollment
11th of 13
28 · median 33
Started
2023
with 1 other
Phase 1
12 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is one of 12 in phase 1, and was the 11th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study.

The purpose of this study is to find out how a medicine called BI 1015550 is taken up in the blood of people with and without liver problems. Liver problems may change how a medicine is processed in the body.

Participants are in the study for about 2 weeks. During this time, they visit the study site 6 times. On the second visit, participants stay overnight at the study site for 4 nights. At the visits, doctors take blood samples to measure the levels of BI 1015550 in participants' blood. Then they compare the results between the groups of participants with and without liver problems. The doctors also check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants
  • Age 18-79 years (inclusive)
  • (BMI) of 18.5 to 35 kilogram per square meter (kg/m2) (inclusive)
  • Signed and dated written in accordance with Guideline for Guideline for Good Clinical Practice - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Male participants are not required to use
  • Women of are allowed to participate provided they use a highly effective contraception from at least 30 days before the administration of trial medication until 7 days after trial completion. Of note, oral hormonal contraceptives are not considered as highly effective in this study due to the potential induction by BI 1015550. Methods of contraception considered adequate for female participants of childbearing potential are listed in the protocol.

Inclusion criteria applying only to participants with impaired hepatic function

  • Hepatic impairment classified as A (score 5-6 points) or Child-Pugh B (score 7-9 points)
  • further inclusion criteria apply

Inclusion criteria applying only to participants with normal hepatic function

  • Individually matched to participants with hepatic impairment according to sex, age, and weight
  • further inclusion criteria apply

Exclusion criteria

Exclusion criteria applying to all participants

  • Any evidence of a concomitant disease assessed as by the investigator
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetic(s) (PK) of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (CNS) (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders (including but not limited to major depressive disorder)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Relevant chronic or acute infections
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin or in situ carcinoma of uterine cervix
  • further exclusion criteria apply

Exclusion criteria applying only to participants with hepatic impairment

  • A marked prolongation of time from the start of the Q wave to the end of the T wave ()/ QT corrected for heart rate (QTc) interval (such as QT Corrected by the Fridericia Formula (QTcF) intervals that are repeatedly greater than 480 milliseconds (ms) in males or repeatedly greater than 500 ms in females) or any other relevant (ECG) finding at screening
  • further exclusion criteria apply

Exclusion criteria applying only to participants with normal hepatic function

  • Any finding in the medical examination (including blood pressure (BP), pulse rate (PR) or ECG) deviating from normal and assessed as clinically relevant by the investigator
  • further exclusion criteria apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    BI 1015550 mild hepatic impairment

    Participants with mild hepatic impairment, classified as Child-Pugh A (score 5 to 6 points), administered orally one film-coated tablet of 18 milligram of BI 1015550 with 240 milliliter of water after an overnight fast of at least 10 hours.

    Drug: BI 1015550

  • Experimental
    BI 1015550 moderate hepatic impairment

    Participants with moderate hepatic impairment, classified as Child-Pugh B (score 7 to 9 points), administered orally one film-coated tablet of 18 milligram of BI 1015550 with 240 milliliter of water after an overnight fast of at least 10 hours.

    Drug: BI 1015550

  • Experimental
    BI 1015550 normal hepatic function

    Participants with normal hepatic function administered orally one film-coated tablet of 18 milligram of BI 1015550 with 240 milliliter of water after an overnight fast of at least 10 hours. Participants with normal hepatic function were individually matched to participants with mild and/or moderate hepatic impairment. The matching criteria were age (± 10 years), sex and weight (± 15%). One participant with normal hepatic function could match one participant in one or both groups of participants with hepatic impairment.

    Drug: BI 1015550

Interventions

  • BI 1015550

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

    Time frame: Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.

  2. Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

    Time frame: Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

    Time frame: Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.

07

Results

Posted Nov 28, 2025

Participant flow

The trial was performed as a non-randomised, single-dose, open-label, parallel, individual matched design in order to investigate pharmacokinetic(s) of BI 1015550, as well as safety and tolerability of BI 1015550 in male and female participants with mild and moderate hepatic impairment compared to individually matched control participants.

Participant flow — Overall Study
MilestoneBI 1015550 mild hepatic impairmentBI 1015550 moderate hepatic impairmentBI 1015550 normal hepatic function
Started8812
Treated8812
Completed8812
Not completed000

Outcome measures

PrimaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

Time frame:
Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/liter (h*nmol/L)BI 1015550 mild hepatic impairmentBI 1015550 moderate hepatic impairmentBI 1015550 normal hepatic function matched to mild hepatic impairmentBI 1015550 normal hepatic function matched to moderate hepatic impairment
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)2913.55 ± NA2837.74 ± NA2786.43 ± NA2168.11 ± NA
Statistical analysis
  • BI 1015550 mild hepatic impairment vs BI 1015550 normal hepatic function matched to mild hepatic impairment · Ratio of adjusted geometric means [%]: 104.56 · 90% CI 91.89 to 118.98Ratio \[%\] = (adjusted geometric mean of mild hepatic impairment / adjusted geometric mean of normal hepatic function matched to mild hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 13.7
  • BI 1015550 moderate hepatic impairment vs BI 1015550 normal hepatic function matched to moderate hepatic impairment · Ratio of adjusted geometric means [%]: 130.89 · 90% CI 89.34 to 191.75Ratio \[%\] = (adjusted geometric mean of moderate hepatic impairment / adjusted geometric mean of normal hepatic function matched to moderate hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 42.0
PrimaryMaximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

Maximum measured concentration of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

Time frame:
Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.
Reported as:
Geometric least squares mean · nanomole/liter (nmol/L)
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)
nanomole/liter (nmol/L)BI 1015550 mild hepatic impairmentBI 1015550 moderate hepatic impairmentBI 1015550 normal hepatic function matched to mild hepatic impairmentBI 1015550 normal hepatic function matched to moderate hepatic impairment
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)409.35 ± NA277.67 ± NA491.48 ± NA404.46 ± NA
Statistical analysis
  • BI 1015550 mild hepatic impairment vs BI 1015550 normal hepatic function matched to mild hepatic impairment · Ratio of adjusted geometric means [%]: 83.29 · 90% CI 60.47 to 114.71Ratio \[%\] = (adjusted geometric mean of mild hepatic impairment / adjusted geometric mean of normal hepatic function matched to mild hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 34.8
  • BI 1015550 moderate hepatic impairment vs BI 1015550 normal hepatic function matched to moderate hepatic impairment · Ratio of adjusted geometric means [%]: 68.65 · 90% CI 46.48 to 101.41Ratio \[%\] = (adjusted geometric mean of moderate hepatic impairment / adjusted geometric mean of normal hepatic function matched to moderate hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 43.0
SecondaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of R-BI 1015550 (the pharmacologically active enantiomer, determined using the chiral bioanalytical assay) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. This model included the effect 'degree of hepatic impairment' as a fixed effect and 'matched pair' as random effect. These quantities were then back-transformed to the original scale. The model was fitted separately for the two hepatic impaired groups.

Time frame:
Within the 2 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 and 144 hours after drug administration.
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/liter (h*nmol/L)BI 1015550 mild hepatic impairmentBI 1015550 moderate hepatic impairmentBI 1015550 normal hepatic function matched to mild hepatic impairmentBI 1015550 normal hepatic function matched to moderate hepatic impairment
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)2964.46 ± NA2866.58 ± NA2811.48 ± NA2186.53 ± NA
Statistical analysis
  • BI 1015550 mild hepatic impairment vs BI 1015550 normal hepatic function matched to mild hepatic impairment · Ratio of adjusted geometric means [%]: 105.44 · 90% CI 92.36 to 120.38Ratio \[%\] = (adjusted geometric mean of mild hepatic impairment / adjusted geometric mean of normal hepatic function matched to mild hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 14.1
  • BI 1015550 moderate hepatic impairment vs BI 1015550 normal hepatic function matched to moderate hepatic impairment · Ratio of adjusted geometric means [%]: 131.10 · 90% CI 89.96 to 191.05Ratio \[%\] = (adjusted geometric mean of moderate hepatic impairment / adjusted geometric mean of normal hepatic function matched to moderate hepatic impairment)\*100. Intra-matched pair geometric coefficient of variation (gCV) \[%\] = 41.4

Adverse events

Collected over From the administration of BI 1015550, until the end of the on-treatment period, up to 7 days. All-cause mortality was recorded from the administration of BI 1015550 until the end of trial, up to 2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1015550 normal hepatic function matched to mild hepatic impairment0/8 (0%)0/8 (0%)2/8 (25%)
BI 1015550 mild hepatic impairment0/8 (0%)0/8 (0%)2/8 (25%)
BI 1015550 normal hepatic function matched to moderate hepatic impairment0/8 (0%)0/8 (0%)1/8 (12.5%)
BI 1015550 moderate hepatic impairment0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventBI 1015550 normal hepatic function matched to mild hepatic impairmentBI 1015550 mild hepatic impairmentBI 1015550 normal hepatic function matched to moderate hepatic impairmentBI 1015550 moderate hepatic impairment
HeadacheNervous system disorders2/80/81/81/8
Abdominal pain upperGastrointestinal disorders0/80/80/81/8
Catheter site inflammationGeneral disorders0/81/80/80/8
Subcutaneous haematomaInjury, poisoning and procedural complications0/81/80/80/8
Lipase increasedInvestigations0/80/80/81/8

Baseline characteristics

Treated set (TS) included all participants who were treated with 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)BI 1015550 Mild Hepatic ImpairmentBI 1015550 Moderate Hepatic ImpairmentBI 1015550 Normal Hepatic FunctionTotal
Mean65.9 ± 5.561.0 ± 7.464.7 ± 9.0464.0 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 Mild Hepatic ImpairmentBI 1015550 Moderate Hepatic ImpairmentBI 1015550 Normal Hepatic FunctionTotal
Female44614
Male44614
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1015550 Mild Hepatic ImpairmentBI 1015550 Moderate Hepatic ImpairmentBI 1015550 Normal Hepatic FunctionTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White881228
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • CRS Clinical Research Services Kiel GmbH
    Kiel, 24105, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Sep 2023, 7 months.

Results were first posted in Nov 2025, 2 years 2 months after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 7 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Dec 22, 2022
StartActual
Feb 7, 2023
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05661344
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Feb 7, 2023
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion